Celsion Announces ThermoDox® HEAT Study Findings To Be Presented at the International Liver Cancer Association (ILCA) 2013

   Celsion Announces ThermoDox® HEAT Study Findings To Be Presented at the
   International Liver Cancer Association (ILCA) 2013 Annual Conference in
                     Washington, DC on September 14, 2013

HEAT Study Will Be One of Four Oral Presentations at the Plenary Session

HEAT Study Selected To Be Included in ILCA Webcast

PR Newswire

LAWRENCEVILLE, N.J., July 11, 2013

LAWRENCEVILLE, N.J., July 11, 2013 /PRNewswire/ -- Celsion Corporation
(NASDAQ: CLSN) announced today that Ronnie T.P. Poon, MD, MS, PhD, FRCS(Edin),
FACS, Professor of Surgery at the University of Hong Kong and Lead Asia
Pacific Principal Investigator for Celsion's Phase III HEAT Study of
ThermoDox® in hepatocellular carcinoma (HCC) will present the clinical trial
results at the International Liver Cancer Association 7^th Annual Conference
being held September 13-15, 2013 in Washington D.C. The presentation will
include data from the HEAT Study post hoc analysis, which suggests positive
progression free survival (PFS) and overall survival (OS) in ThermoDox®
treated patients when heating cycles from the radiofrequency ablation (RFA)
procedure were optimized.

Professor Poon's oral presentation, titled "Phase 3 Randomized, Double-Blind,
Dummy-Controlled Trial of Radiofrequency Ablation (RFA) + Lyso-Thermosensitive
Liposomal Doxorubicin for Hepatocellular Carcinoma (HCC) Lesions 3-7 cm," will
be held Saturday, September 14, 2013 at 12:00 p.m. (local time) in the Plenary
Session. ILCA has selected the HEAT Study presentation to be webcast as part
of an online educational program of the ILCA 2013 Annual Conference. Dr.
Poon's presentation will be made available online after the conference.

The International Liver Cancer Association is the only international
organization devoted exclusively to liver cancer research for experts from all
related disciplines-- medical, interventional and surgical oncology as well
as hepatology. ILCA's Executive Committee consists of Dr. Josep M. Llovet
(President); Professor Riccardo Lencioni and Dr. Morris Sherman. Professor
Lencioni co-chaired a session devoted to radiofrequency ablation at the 2013
European Conference on Interventional Oncology held in Budapest, Hungary on
June 19, 2013 during which he discussed the HEAT Study results and the
emerging post hoc analysis data.Celsion also notes that Professors Lencioni
and Poon and Dr. Sherman are principal investigators on the HEAT Study.

Celsion has conducted a comprehensive analysis of the data from the Phase III
HEAT Study of ThermoDox® in HCC, also known as primary liver cancer, with key
principal investigators, data experts and liver cancer experts including
Professors Lencioni and Poon. Emerging data from the HEAT Study post hoc
analysis demonstrates that ThermoDox® markedly improves PFS and overall
survival in patients if their lesions undergo RFA for 45 minutes or more.
These findings apply to HCC lesions from both size cohorts of the HEAT Study
(3-5 cm and 5-7 cm) and represent a sizable subgroup of approximately 300
patients.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology. Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford. For more information on Celsion, visit
our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; HEAT Study data is subject to further
verification and review by the HEAT Study Data Management Committee; the need
for Celsion to evaluate its future development plans; termination of the
Technology Development Contract or collaboration between Celsion and HISUN at
any time; possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or licenses;
possible actions by customers, suppliers, competitors, regulatory authorities;
and other risks detailed from time to time in the Celsion 's periodic reports
and prospectuses filed with the Securities and Exchange Commission. Celsion
assumes no obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church
Senior Vice President
609-482-2455
jchurch@celsion.com



SOURCE Celsion Corporation

Website: http://www.celsion.com
 
Press spacebar to pause and continue. Press esc to stop.